Have questions? reach out
Have questions? reach out
After identifying your targets of interest—through WBL services or other methods—our scientists collaborate with you to develop customized targeting solutions optimized for your project’s goals.
[ Biomarker Discovery ]
[ Targeted Sequencing ]
[ Deployment ]
After identifying your targets of interest—through WBL services or other methods—our scientists collaborate with you to develop customized targeting solutions optimized for your project’s goals.
Meet with our team to explore your therapeutic area of interest, establish clear objectives, and determine the optimal approach for your desired endpoints.
Leverage our biomarker discovery services to identify genes, regions, or other genomic features critical to your project.
Utilize hybridization-based enrichment with optimized oligonucleotide probes or bioinformatic targeting to analyze specific regions of interest.
Meet with our team to explore your therapeutic area of interest, establish clear objectives, and determine the optimal approach for your desired endpoints.
RUO
GCP
CLIA (NYS)
[Solution 01]
WBL offers custom bioinformatic solutions to balance breadth, precision, and efficiency for genomic and methylation panels. Pairing biomarker discovery services with custom bioinformatic pipelines to target regions of interest, WBL’s approach reduces noise and redundancy, delivering high-quality results for methylation and native DNA studies at any scale.
Figure 2A. Quantitative Identification of Tissue-Specific Methylation with dMS. Correlations between predicted and actual fractions of Tissue 1-derived DNA show high accuracy with 2,000 randomly selected reads, demonstrating the precision of dMS
Figure 2B. Sensitive Detection of Low-Concentration DNA with dMS. dMS achieves accurate detection of Tissue 1-specific DNA at low concentrations, with high correlation (R² = 0.997) even with fewer than 100 reads per dilution.
Identifying DNA’s cell or tissue of origin through methylation analysis has significant clinical applications, but its use in diagnostics has been limited by bisulfite sequencing biases and restricted target coverage. WBL’s dMS enables precise tissue-of-origin determination by detecting complex tissue-specific methylation signatures.
DNA from Tissue 1 and Tissue 2 was sequenced with dWMS. Bioinformatic targeting of 8,457 Tissue 1-specific regions allowed accurate identification (Figure 2A, 2B).
From exploratory research to targeted analyses, Wasatch BioLabs empowers precision analysis with unbiased sequencing solutions. Leveraging proprietary technologies like dTMS, tailored workflows, and expert bioinformatics support, we deliver actionable insights to advance your research.
[Service]
Harness advanced tools like dTMS to develop targeted panels, analyze complex variants, and detect epigenetic modifications with scalable workflows for clinical applications.
[Service]
Enhance your data with custom bioinformatics solutions, using tailored workflows and advanced analysis to generate impactful, publication-ready insights.
[Service]
Work with native-read sequencing experts with decades of experience in genomics, epigenomics, and bioinformatics to guide your project from discovery to clinical success.
Wasatch BioLabs provides end-to-end custom assay development, including biomarker discovery, targeted assay design, workflow optimization, and regulatory-grade validation. We support projects ranging from research use only (RUO) to clinical deployment, with tailored workflows aligned to GCP, CLIA, CLEP, and FDA requirements.
Wasatch BioLabs begins with a collaborative planning process to define research objectives and clinical context. We then design and optimize targeted assays, using hybridization- or bioinformatics-based approaches, aligned to your biological questions, accuracy requirements, and scalability needs.
Custom assays can include a broad range of genomic and epigenomic targets, such as tissue-specific methylation signatures, structural variants, single nucleotide variants, and disease- or expression-associated regions. Wasatch BioLabs designs panels across these features with native sequencing assays, including dMS, dWMS, and dTMS.
Custom assay development at Wasatch BioLabs typically includes discovery and planning, assay design, optimization and validation, and deployment for research use or regulatory-aligned applications. Timelines vary depending on assay complexity, sample type, and regulatory requirements, and are discussed during project planning.
Yes, Wasatch BioLabs’ custom assays are designed to integrate seamlessly with Oxford Nanopore native-read sequencing and can be incorporated into existing analysis pipelines. Our bioinformatics tools support straightforward integration for variant detection, methylation profiling, and expression analysis.
Wasatch BioLabs provides fit-for-purpose validation aligned to your intended use, from research use only (RUO) to GCP-, CLIA-, CLEP-, and FDA-aligned applications. Our clinical-grade laboratory infrastructure and quality management system ensures custom assays meet relevant regulatory and performance requirements.
To initiate a project, contact Wasatch BioLabs through our website or email our support team at support@wasatchbiolabs.com. Our scientists will work with you to define project goals and guide you through planning, assay design, and implementation to ensure alignment with your research or clinical needs.
